Evidence map›Paper›PMID 33340431›Full record

ArticleCancer science2021

MTA2 promotes the metastasis of esophageal squamous cell carcinoma via EIF4E-Twist feedback loop.

Su-Li Dai, Si-Si Wei, Cong Zhang, Xiao-Ya Li, Yue-Ping Liu, Ming Ma, Hui-Lai Lv, Zhenzhen Zhang, Lian-Mei Zhao, Bao-En Shan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Review
  11. Article
  12. Long Non-coding RNAs WithCancer genomics & proteomics
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Su-Li DaiResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.ORCID https://orcid.org/0000-0003-2337-1149
Si-Si WeiResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Cong ZhangResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Xiao-Ya LiResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Yue-Ping LiuDepartment of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Ming MaResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Hui-Lai LvDepartment of Fifth Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Zhenzhen ZhangDivision of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Lian-Mei ZhaoResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Bao-En ShanResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Hebei Medical University · CNOregon Health & Science University · US

Funding

Financial Department of Hebei province 20201067National Natural Science Foundation of China 81673642National Natural Science Foundation of China 81772550Natural Science Foundation of Hebei Province H2019206697
6 · The paper itself

Abstract

Metastasis-associated protein 2 (MTA2) is frequently amplified in many types of cancers; however, the role and underlying molecular mechanism of MTA2 in esophageal squamous cell carcinoma (ESCC) remain unknown. Here, we reported that MTA2 is highly expressed in ESCC tissue and cells, and is closely related to the malignant characteristics and poor prognosis of patients with ESCC. Through in vitro and in vivo experiments, we demonstrated that MTA2 significantly promoted ESCC growth, metastasis, and epithelial-mesenchymal transition (EMT) progression. This integrative analysis combined with expression microarray showed that MTA2 could interact with eukaryotic initiation factor 4E (EIF4E), which positively regulates the expression of Twist, known as a master regulator of EMT. Moreover, the results of chromatin immunoprecipitation revealed that MTA2 was recruited to the E-cadherin promoter by Twist, which reduced the acetylation level of the promoter region and thus inhibited expression of E-cadherin, and subsequently promoted the aggressive progression of ESCC. Collectively, our study provided novel evidence that MTA2 plays an aggressive role in ESCC metastasis by a novel EIF4E-Twist positive feedback loop, which may provide a potential therapeutic target for the management of ESCC.

Indexed as

AnimalsAntigens, CDCadherinsCell Line, TumorEpithelial-Mesenchymal TransitionEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaEsophagectomyEsophagusEukaryotic Initiation Factor-4EFeedback, PhysiologicalFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesHistone DeacetylasesHumansAntigens, CDCadherinsCDH1 protein, humanEIF4E protein, humanEukaryotic Initiation Factor-4EHistone DeacetylasesMTA2 protein, humanNuclear ProteinsRepressor ProteinsTWIST1 protein, humanTwist-Related Protein 1EIF4EESCCmetastasisMTA2Twist

Identifiers

PMID33340431
PMCPMC7935808
OpenAlexW3114135285

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.